North America Hereditary Cancer Testing Market

The North America hereditary cancer testing market is expected to reach US$ 3,247.37 Mn in 2027 from US$ 1,255.79 Mn in 2018. The market is estimated to grow with a CAGR of 11.6% from 2019-2027.

The growth of the market is driven by factors such as, growing awareness about hereditary cancer and favorable reimbursement scenario. However, market growth is likely to slow down due to the gender gap in cancer genetic testing in the region.

Personalized medicines is a comparatively new idea that allows doctors to select medication based on a patient's hereditary profile; it is a developing area in the healthcare sector. The method not only reduces adverse side effects but also manages to produce strong results in a short period. For instance, mutations in BRCA1 and BRCA2 lead to breast cancer. However, identifying the type of variation in the breast cancer patient provides crucial information for the kind of treatment. Hence, personalized medicines allow right treatment at the right time, which reduces the mortality rate. On the back of these advantages, the personalized medicine approach is likely to create many opportunities for the hereditary cancer testing market players.

The US is expected to lead the market in the North America region to the rapidly increasing expenditure of research and development by biopharmaceutical companies. Moreover, various biopharmaceutical companies are focusing on the development of new cancer panel and direct to consumer test. Therefore, considering the factors mentioned above, growth of the market in the US is likely to contribute the most significant share in the North America region during the forecast period.

Mexico Hereditary cancer testing Market Revenue and Forecasts to 2027 (US$ Mn)

North America Hereditary Cancer Testing Strategic Insights

Strategic insights for the North America Hereditary Cancer Testing provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Hereditary Cancer Testing Report Scope

North America Hereditary Cancer Testing Regional Insights

The geographic scope of the North America Hereditary Cancer Testing refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

NORTH AMERICA HEREDITARY CANCER TESTING – MARKET SEGMENTATION

 BY DIAGNOSIS TYPE

• Biopsy
  • Blood Sample
  • Cheek Swab Sample
• Imaging

BY

TECHNOLOGY

• Sequencing
• PCR
• Microarray

BY END USER

• Diagnostic Centers
• Hospital
• Clinics

Company Profiles

• Biosero Inc.
• Hologic Inc.
• Koninklijke Philips N.V.
• Quest Diagnostics Incorporated
• Myriad Genetics, Inc.
• Cancer Genetics Inc.
• Invitae Corporation
• Myogenes
• Strand Life Sciences Pvt. Ltd.
• Pathway Genomics Corporation
• CENTOGENE AG